No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2006 ASCO Annual Meeting. This abstract does not include a full text component.
Final results from PROGRESS trial of sargramostim (GM-CSF) in combination with irinotecan (I), 5-fluorouracil (F), and leucovorin (L) for metastatic colorectal cancer (CRC) No significant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results